HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bennett-Guerrero, E. Articles by Ortel, T. L. Search for Related Content PubMed PubMed Citation Articles by Bennett-Guerrero, E. Articles by Ortel, T. L. Related Collections Cardiac - other Extracorporeal circulation

J Thorac Cardiovasc Surg 2005;130:1567-1572
© 2005 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery

^a Departments of Anesthesiology
^c Hematology, Duke University Medical Center, Durham, NC
^b Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC

Received for publication February 11, 2005; revisions received April 14, 2005; accepted for publication July 29, 2005.

^_* Address for reprints: Elliott Bennett-Guerrero, MD, Duke Clinical Research Institute, Duke University (DUMC Box 3094), Durham, NC 27710 (Email: elliott.bennettguerrero{at}duke.edu).

OBJECTIVE: Preexisting serum antibodies to heparin/platelet factor 4 complexes may predispose adult cardiac surgical patients to increased perioperative morbidity and mortality. We sought to determine the association between preoperative serum antibodies directed against platelet factor 4/heparin complexes and major complications (in-hospital death or length of stay >10 days) in adult cardiac surgical patients.

METHODS: In a prospective observational study of 466 patients undergoing elective coronary artery bypass grafting, valvular heart surgery, or both, preoperative serum was assayed for anti–platelet factor 4/heparin antibody by using a commercially available enzyme-linked immunosorbent assay (Asserachrom HPIA). Known preoperative risk factors were assessed, and patients were assigned a risk score by using the validated method of Parsonnet and colleagues.

RESULTS: Major complications (death or postoperative hospitalization >10 days) occurred in 108 patients (23%). Overall, 59 (13%) patients had a positive preoperative anti–platelet factor 4/heparin antibody screen (upper limit of normal is 0.5 optical density units). A positive assay result independently predicted an increased risk of major complications (P = .0284; odds ratio, 1.98; 95% confidence interval, 1.06-3.62) over and above the effect of the Parsonnet risk score (P < .001; odds ratio, 1.07; 95% confidence interval, 1.05-1.10). The level of preoperative anti–platelet factor 4/heparin antibody was also significantly associated with major complications (P = .036; odds ratio, 1.31; 95% confidence interval, 1.02-1.68) independently of the Parsonnet risk score. No association (P > .75) existed between the Parsonnet risk score and preoperative anti–platelet factor 4/heparin antibody level.

CONCLUSIONS: Serum antibodies directed against platelet factor 4/heparin complexes are prevalent in the adult patient population undergoing cardiac surgery. The presence of these antibodies before surgery is an independent predictor for death or prolonged hospitalization after adult cardiac surgery.

This article has been cited by other articles:

				D. Paparella, G. Scrascia, A. Galeone, M. Coviello, G. Cappabianca, M. T. Venneri, B. Favoino, M. Quaranta, L. de Luca Tupputi Schinosa, and T. E. Warkentin Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1456 - 1463. [Abstract] [Full Text] [PDF]

				J. G. Kelton and T. E. Warkentin Heparin-induced thrombocytopenia: a historical perspective Blood, October 1, 2008; 112(7): 2607 - 2616. [Full Text] [PDF]

				Q. A Czosnowski, S. W Finks, and K. C Rogers Bivalirudin for Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery Ann. Pharmacother., September 1, 2008; 42(9): 1304 - 1309. [Abstract] [Full Text] [PDF]

				A. Greinacher and J. H. Levy HIT Happens: Diagnosing and Evaluating the Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., August 1, 2008; 107(2): 356 - 358. [Full Text] [PDF]

				M. P. Mullen, D. L. Wessel, K. C. Thomas, K. Gauvreau, E. J. Neufeld, F. X. McGowan Jr, and J. A. DiNardo The Incidence and Implications of Anti-Heparin-Platelet Factor 4 Antibody Formation in a Pediatric Cardiac Surgical Population Anesth. Analg., August 1, 2008; 107(2): 371 - 378. [Abstract] [Full Text] [PDF]

				S. M. Dellaria, P. E. Greilich, and R. Sarode Urgent Cardiac Surgery in a Patient with a Remote History of Heparin-Induced Thrombocytopenia: Use of the Anti-PF4/Heparin ELISA Confirmatory Test Anesth. Analg., August 1, 2008; 107(2): 379 - 381. [Abstract] [Full Text] [PDF]

				D Alpert, L A Mandl, D Erkan, W Yin, E I Peerschke, and J E Salmon Anti-heparin platelet factor 4 antibodies in systemic lupus erythaematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome Ann Rheum Dis, March 1, 2008; 67(3): 395 - 401. [Abstract] [Full Text] [PDF]

				I. Apostolidou, M. F. Sweeney, E. Missov, L. D. Joyce, R. John, and R. C. Prielipp Acute Left Atrial Thrombus After Recombinant Factor VIIa Administration During Left Ventricular Assist Device Implantation in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., February 1, 2008; 106(2): 404 - 408. [Abstract] [Full Text] [PDF]

				C. M. Dyke, G. Aldea, A. Koster, N. Smedira, E. Avery, S. Aronson, B. D. Spiess, and A. M. Lincoff Off-Pump Coronary Artery Bypass With Bivalirudin for Patients With Heparin-Induced Thrombocytopenia or Antiplatelet Factor Four/Heparin Antibodies Ann. Thorac. Surg., September 1, 2007; 84(3): 836 - 839. [Abstract] [Full Text] [PDF]

				J. H. Levy, K. A. Tanaka, and M. J. Hursting Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia Anesth. Analg., September 1, 2007; 105(3): 570 - 582. [Abstract] [Full Text] [PDF]

				D. C. Kress, S. Aronson, M. L. McDonald, M. I. Malik, A. B. Divgi, A. J. Tector, F. X. Downey III, A. J. Anderson, M. Stone, and C. Clancy Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgical Outcomes Ann. Thorac. Surg., May 1, 2007; 83(5): 1737 - 1743. [Abstract] [Full Text] [PDF]

				B. M. Everett, R. Yeh, S. Y. Foo, D. Criss, E. M. Van Cott, M. Laposata, E. G. Avery, W. D. Hoffman, J. Walker, D. Torchiana, et al. Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery Ann. Thorac. Surg., February 1, 2007; 83(2): 592 - 597. [Abstract] [Full Text] [PDF]